Published :
Tables : 62
Figures : 50
Category : Healthcare
No. of Pages : 233
Report Code : HC-U3319
Molecular Cytogenetics Market is estimated to value over USD 3.24 billion by 2027 end with a CAGR of over 10.9% during the forecast period 2020 to 2027. The increasing prevalence of genetic disorders, improving healthcare infrastructure, increased adoption of molecular cytogenic products in research and clinical laboratories, pharmaceutical and biotech companies and academic institutes and increased emphasis on targeted treatment of cancer are some of the crucial factors responsible for the growth of the market. The cytogenic analysis earlier focused only on investigating the cellular aspects that detected the genomic aberrations and studying the structure of chromosome in heredity conditions. Currently, cytogenic analysis is being extensively used for applications others than identifying a genome’s chromosomal status, which has enhanced the study of changes in the chromosome involved in the pathogenesis of a disease, the human genome organization in three dimensions. Human genetics is prominently used for bridging the gap between the provisions of a refined medical service and the applications of findings of genes. Such a broad range of applications shall augment the market growth. Additionally, the rising prevalence of cancer and increased mortality rate annually has substantially helped in the molecular cytogenetics market growth. Such a consistent rise in new cancer cases has increased the necessity for developing novel technologies for a completer understanding of cancer genomically. Some of the recognised cytogenic methods like Comparative Genomic Hybridization and FISH that offer extensive insights about the molecular signatures related to cancer, thereby gaining information on the progression of cancer. Increased pharmacogenomic activities are predicted to substantially influence the proliferation of the market. However, the reimbursement policies for molecular cytogenetics are unfavourable and these instruments being expensive, the treatments are meant to be expensive as well, thereby negatively affecting the growth of the market. Market Segmentation: By Technology • Fluorescence In-Situ Hybridization • Comparative Genomic Hybridization • In-Situ Hybridization • Karyotyping • Banding Techniques By Product • Instruments • Kits and Reagents • Software • Services • Consumables/Accessories By Application • Oncology • Genetic Disorders • Personalized Medicines • Others By End User • Pharmaceutical and Biotechnological Companies • Clinical and Diagnostic Laboratories • Academic Institutes • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa The market is fragmented into technology, product, application, end user and region. The technology segment is categorised into fluorescence in-situ hybridization (FISH), comparative genomic hybridization (CGH), in-situ hybridization, karyotyping and bandaging techniques. The CGH technology is anticipated to hold the largest molecular cytogenetics market share owing to the ease of availability, reduced turnaround time, reduced cost and efficient specificity and increased adoption of these technologies across a variety of applications like medicinal development, research activities and diagnostics. Such benefits of FISH and CGH technologies over traditional methods shall proliferate the growth of the market. The product segment is divided into instruments, kits and reagents, software, services and consumables. The kits and reagents segment is anticipated to lead the market during the forecast period owing to the increased usage of reagents and kits during cytogenetic analysis and the ability to gain reproducible and accurate results in advanced and standard cytogenetic clinical protocols. However, the software and services segments are anticipated to grow at a substantial rate due to the current development in algorithms and solutions for managing and interpreting huge volumes of genomic data. The application segment is categorised into oncology, genetic disorders, personalised medicines and others. The personalised medicine segment is poised to dominate the market owing to it wide range of applications in cytogenomics, cytoproteomics, biomarker discovery and drug development and discovery. The end user segment is divided into pharmaceutical and biotechnological companies, clinical and diagnostic laboratories and others. The clinical and research laboratories segment subjugated the market due to the rising usage of cytogenetic methods for clinical diagnosis. Regional Analysis: The North America region is predicted to lead the global market owing to a strong presence of major market players, implementation of an efficient regulatory framework for regulating genetic tests. The Asia Pacific region, however, is anticipated to grow at a significant rate during the forecast period. This is mainly due to the consistent rise in the gross domestic product of nations like India, Japan which shall enhance the buying drive and power of the consumer. Competitive Landscape: The prominent market players are Thermo Fisher Scientific, Abbott Laboratories, Agilent Technologies, PerkinElmer, Bio-Rad Laboratories, Applied Spectral Imaging, Quest Diagnostics, Roche Diagnostics, Danaher Corporation, Illumina, Oxford Gene Technology. FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the global molecular cytogenetics market by technology, by product, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The increasing prevalence of genetic disorders, improving healthcare infrastructure, increased adoption of molecular cytogenic products in research and clinical laboratories, pharmaceutical and biotech companies and academic institutes and increased emphasis on targeted treatment of cancer are some of the crucial factors responsible for the growth of the market. The cytogenic analysis earlier focused only on investigating the cellular aspects that detected the genomic aberrations and studying the structure of chromosome in heredity conditions. Currently, cytogenic analysis is being extensively used for applications others than identifying a genome’s chromosomal status, which has enhanced the study of changes in the chromosome involved in the pathogenesis of a disease, the human genome organization in three dimensions. Human genetics is prominently used for bridging the gap between the provisions of a refined medical service and the applications of findings of genes. Such a broad range of applications shall augment the market growth. Additionally, the rising prevalence of cancer and increased mortality rate annually has substantially helped in the molecular cytogenetics market growth. Such a consistent rise in new cancer cases has increased the necessity for developing novel technologies for a completer understanding of cancer genomically. Some of the recognised cytogenic methods like Comparative Genomic Hybridization and FISH that offer extensive insights about the molecular signatures related to cancer, thereby gaining information on the progression of cancer. Increased pharmacogenomic activities are predicted to substantially influence the proliferation of the market. However, the reimbursement policies for molecular cytogenetics are unfavourable and these instruments being expensive, the treatments are meant to be expensive as well, thereby negatively affecting the growth of the market.
Market Segmentation:
By Technology • Fluorescence In-Situ Hybridization • Comparative Genomic Hybridization • In-Situ Hybridization • Karyotyping • Banding Techniques By Product • Instruments • Kits and Reagents • Software • Services • Consumables/Accessories By Application • Oncology • Genetic Disorders • Personalized Medicines • Others By End User • Pharmaceutical and Biotechnological Companies • Clinical and Diagnostic Laboratories • Academic Institutes • Others By Region • North America • Europe • Asia-Pacific • Latin America • Middle East and Africa
The market is fragmented into technology, product, application, end user and region. The technology segment is categorised into fluorescence in-situ hybridization (FISH), comparative genomic hybridization (CGH), in-situ hybridization, karyotyping and bandaging techniques. The CGH technology is anticipated to hold the largest molecular cytogenetics market share owing to the ease of availability, reduced turnaround time, reduced cost and efficient specificity and increased adoption of these technologies across a variety of applications like medicinal development, research activities and diagnostics. Such benefits of FISH and CGH technologies over traditional methods shall proliferate the growth of the market. The product segment is divided into instruments, kits and reagents, software, services and consumables. The kits and reagents segment is anticipated to lead the market during the forecast period owing to the increased usage of reagents and kits during cytogenetic analysis and the ability to gain reproducible and accurate results in advanced and standard cytogenetic clinical protocols. However, the software and services segments are anticipated to grow at a substantial rate due to the current development in algorithms and solutions for managing and interpreting huge volumes of genomic data. The application segment is categorised into oncology, genetic disorders, personalised medicines and others. The personalised medicine segment is poised to dominate the market owing to it wide range of applications in cytogenomics, cytoproteomics, biomarker discovery and drug development and discovery. The end user segment is divided into pharmaceutical and biotechnological companies, clinical and diagnostic laboratories and others. The clinical and research laboratories segment subjugated the market due to the rising usage of cytogenetic methods for clinical diagnosis.
Regional Analysis:
The North America region is predicted to lead the global market owing to a strong presence of major market players, implementation of an efficient regulatory framework for regulating genetic tests. The Asia Pacific region, however, is anticipated to grow at a significant rate during the forecast period. This is mainly due to the consistent rise in the gross domestic product of nations like India, Japan which shall enhance the buying drive and power of the consumer.
Competitive Landscape:
The prominent market players are Thermo Fisher Scientific, Abbott Laboratories, Agilent Technologies, PerkinElmer, Bio-Rad Laboratories, Applied Spectral Imaging, Quest Diagnostics, Roche Diagnostics, Danaher Corporation, Illumina, Oxford Gene Technology.
FutureWise Key Takeaways:
• Growth prospects • SWOT analysis • Key market trends • Key data-points affecting market growth
Objectives of the Study:
• To provide with an exhaustive analysis on the global molecular cytogenetics market by technology, by product, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization Mobility Care offered are free of charge with purchase of any license of the report • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1 Objectives of the Study 1.2 Market Definition 1.3 Market Scope 1.3.1 Years Considered for the Study 1.3.2 Market Covered 1.4 Currency 1.5 Limitations 1.6 Stakeholders 2. Research Methodology 2.1 Research Data 2.1.1 Secondary Data 2.1.1.1 Key Data from Secondary Sources 2.1.2 Primary Data 2.1.2.1 Key Data from Primary Sources 2.2 Market Size Estimation 2.3 Market Breakdown and Data Triangulation 2.4 Assumptions for the Study 3. Executive Summary 3.1 Market Outlook 3.2 Segment Outlook 3.3 Competitive Insights 4. Market Variables, Trends & Scope 4.1 Market Lineage Outlook 4.2 Penetration and Growth Prospect Mapping 4.3 Industry Value Chain Analysis 4.4 Cost Analysis Breakdown 4.5 Technology Overview 4.6 Regulatory Framework on Country Level 4.6.1 Reimbursement Framework 4.6.2 Standards and Compliances 5. Market Overview 5.1 Market Dynamics 5.1.1 Market Driver Analysis 5.1.2 Market Restraint Analysis 5.1.3 Industry Challenges 6. Market Analysis tools 6.1 Industry Analysis - Porter’s 6.1.1 Supplier Power 6.1.2 Buyer Power 6.1.3 Substitution Threat 6.1.4 Threat from new entrants 6.1.5 Competitive Rivalry 6.2 Pestel Analysis 6.2.1 Political Landscape 6.2.2 Environmental Landscape 6.2.3 Social landscape 6.2.4 Technology landscape 6.2.5 Legal Landscape 7. Molecular Cytogenetics Market, By Technology Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 7.1 Fluorescence In-Situ Hybridization 7.2 Comparative Genomic Hybridization 7.2.1 Chromosomal CGH 7.2.2 Array Based CGH 7.3 In-Situ Hybridization 7.4 Karyotyping 7.4.1 Spectral Karyotyping 7.4.2 Virtual karyotyping 7.5 Banding Techniques 7.5.1 G Banding 7.5.2 Q Banding 7.5.3 R Banding 7.5.4 C Banding 7.5.5 T Banding 8. Molecular Cytogenetics Market, By Product Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 8.1 Instruments 8.1.1 Systems 8.1.2 Imagers and Scanners 8.2 Kits and Reagents 8.2.1 Testing Kits 8.2.2 probes 8.2.3 Reagents 8.3 Software 8.4 Services 8.5 Consumables/Accessories 9. Molecular Cytogenetics Market, By Application Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 9.1 Oncology 9.2 Genetic Disorders 9.3 Personalized Medicines 9.4 Others 10. Molecular Cytogenetics Market, By End User Historical Analysis 2015 to 2019 and Forecast 2020-2027 (USD million) 10.1 Pharmaceutical and Biotechnological Companies 10.2 Clinical and Diagnostic Laboratories 10.3 Academic Institutes 10.4 Others 11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Mn) Analysis By Country, 2015-2019 11.2.1. U.S. 11.2.2. Canada 11.2.3. Mexico 11.2.4. Rest of North America 11.3 Market Size (USD Mn) Forecast for North America 2020-2027 12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Regional Market Trends 12.3. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 12.3.1. Brazil 12.3.2. Venezuela 12.3.3. Argentina 12.3.4. Rest of Latin America 12.4 Market Size (US$ Mn) Forecast for Latin America 2020-2027 13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (US$ Mn) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5 Switzerland 13.2.6. Spain 13.2.7. Russia 13.2.8. Poland 13.2.9. Rest of Western Europe 13.3 Market Size (US$ Mn) Forecast for Europe 2020-2027 14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1 Introduction 14.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 14.2.1 Japan 14.2.2 China 14.2.3 Singapore 14.2.4 Korea 14.2.5 India 14.2.6 Australia and New Zealand 14.2.7 ASEAN 14.2.8 Rest of Asia Pacific 14.3 Market Size (US$ Mn) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1 Introduction 15.2 Historical Market Size (USD Mn) Analysis By Country, 2015-2019 15.2.1 UAE 15.2.2 South Africa 15.2.3 Egypt 15.2.4 Saudi Arabia 15.2.5 Rest of MEA 15.3 Market Size (US$ Mn) Forecast for MEA 2020-2027 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts) 16.1 Thermo Fisher Scientific 16.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2 Abbott Laboratories 16.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3 Agilent Technologies 16.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4 PerkinElmer 16.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5 Bio-Rad Laboratories 16.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6 Applied Spectral Imaging 16.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7 Quest Diagnostics 16.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8 Roche Diagnostics 16.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9 Danaher Corporation 16.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10 Illumina 16.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 16.11 Oxford Gene Technology 16.11.1. Company Overview (HQ, Business Segments, Employee Strength) 16.11.2. Product Portfolio 16.11.3. SWOT Analysis 16.11.4. Financial Overview 16.11.5. Strategic Overview 17. Impact of COVID-19 17.1. Positive influence on the healthcare industry 17.2. The financial disruption of the manufacturing sector 17.3. Impact of COVID-19 on emerging companies 17.4. Significant mandates in the healthcare regulations initiated by administrations 17.5. The overall economic slowdown of the developing and developed nations 18. Competitive Intelligence and Competitive Matrix 18.1 Competitive Intelligence 18.2 Competitive Matrix 19. Major Deals and Strategic Alliances Analysis 19.1 Joint ventures 19.2 Mergers and acquisitions 19.3 Licensing and partnerships 19.4 Technology Collaborations 19.5 Strategic Divestments 19.6 Market Entry Strategies 20. Relevant Case Studies and Latest News Updates 21. Research Sources and List of Primary Contacts of this Study 22. Key Market Takeaway Points from the Market Analysts at Future Market Analytics
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics